Bristol Myers Squibb said CheckMate -274, a pivotal phase III trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).
Treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival in patients with early-stage, non-small cell lung cancer with epidermal growth factor receptor gene mutation, according to updated findings led by researchers at Yale Cancer Center.
Back in the 1960s, the American Cancer Society first began promoting the Pap smear as an effective means of cervical cancer screening. A decade later, early detection of breast cancer through mammography became mainstream.
The Lymphoma Research Foundation has announced the establishment of the Jaime Peykoff Follicular Lymphoma Initiative, named for follicular lymphoma survivor and wife of Andrew Peykoff II, owner of Niagara Bottling.
The Mark Foundation for Cancer Research is announcing the launch of a funding program that supports the development of novel cancer therapeutics in areas with high unmet needs. These Drug Discovery Partnership awards are structured to support high-risk, high-reward research and bridge the substantial gap in advancing promising academic discoveries to novel therapies.
After 15 years in the role, C. Kent Osborne has stepped down as director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, the institution said.
Ruben Mesa was named executive director of the Mays Cancer Center. His appointment includes academic and research programming, as well as leading the cancer center's patient care and clinical programs of the UT Health San Antonio MD Anderson affiliation.
Stephen Gruber was named director of City of Hope's newly founded Center for Precision Medicine. He will lead a team of more than 14 researchers focused on personalized cancer prevention and treatment plans.
Deirdre J. Cohen, an expert in pancreatic and other gastrointestinal cancers, was named director of the Gastrointestinal Oncology Program and medical director of the Cancer Clinical Trials Office at The Tisch Cancer Institute at Mount Sinai Health System.
James B. Yu, was named associate chief medical officer for radiation oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network.
